Sacituzumab Govitecan clinical trials
7 indexed studies · 1 currently recruiting
- RecruitingPHASE1, PHASE2
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
This study looks at different treatment combinations for advanced breast cancer, including those that have spread or are hard to remove. Doctors want to see how well these new drug combinations work and if they are safe for patients.
For: Metastatic Breast CancerUnited States · Australia · France - Active not recruitingPHASE3
Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)
This study looks at a new combination treatment for advanced lung cancer. It compares giving a well-known drug (pembrolizumab) with or without an additional drug (sacituzumab govitecan) to see which is better at slowing the cancer's growth and helping people live longer.
For: Carcinoma, Non-Small-Cell LungUnited States · Australia · Brazil - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
A phase Ib/II single-arm, multicenter study of sacituzumab-govitecan, a TROP-2 targeting antibody linked with SN38, for patients with metastatic esophagogastric adenocarcinoma
This study is testing a new medicine, Sacituzumab Govitecan, for people with advanced oesophageal or stomach cancer that has spread. It aims to see how well the medicine works by checking if tumours shrink. This is an early-stage study to learn more about this treatment.
For: metastatic esophagogastric adenocarcinoma (Stage IV)Germany · Austria - Ongoing, recruitingPhase II and Phase III (Integrated)
A randomized, open label, multicenter phase II/III trial of sacituzumab govitecan compared to standard of care in metastatic, refractory colorectal cancer patients (TROPHIT1)
This study is looking at a new treatment called sacituzumab govitecan for bowel cancer that has spread and isn't responding to other treatments. It compares this new drug to standard treatments to see which works best at stopping the cancer from growing.
For: Metastatic Colorectal cancer (mCRC)Germany - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
A Phase I/II, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF1001 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications
This study is testing a new treatment, DF1001, for advanced or spreading cancers. It will look at how safe the treatment is, what side effects it causes, and how it affects the body. Researchers also want to see if it can help shrink tumours or stop them from growing.
For: Locally Advanced or Metastatic Solid Tumors · and Expansion in Selected IndicationsDenmark · Netherlands · Belgium - Active not recruitingPHASE2
A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)
This study looks at new ways to treat advanced bladder cancer using a drug called avelumab, often combined with other medicines. Researchers want to see if these combinations are safe and effective in helping patients whose cancer has spread or is hard to treat.
For: Locally Advanced or Metastatic Urothelial CarcinomaUnited States · Australia · Belgium - AuthorisedTherapeutic exploratory (Phase II)
ALTER : A Phase 2, Multicenter, Randomized, Open-label trial assessing sacituzumab-govitecan and trastuzumab-deruxtecan combinaison in an ALTERnating regimen for patients with metastatic or locally advanced Her2-low triple-negative breast Cancer
This study looks at a new way to treat an advanced type of breast cancer (HER2-low triple-negative breast cancer). It combines two existing medicines, sacituzumab govitecan and trastuzumab deruxtecan, given in an alternating pattern, to see if this helps people live longer.
For: Patients with metastatic or locally advanced HER2-low triple-negative breast cancer and eligible to receive sacituzumab-govitecan and T-Dxd according to their indication.France